Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

BACKGROUND: Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly selective, central nervous system-active TRK inhibitor approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, James C. H., Brose, Marcia S., Castro, Gilberto, Kim, Edward S., Lassen, Ulrik N., Leyvraz, Serge, Pappo, Alberto, López-Ríos, Fernando, Reeves, John A., Fellous, Marc, Penault-Llorca, Frédérique, Rudzinski, Erin R., Tabatabai, Ghazaleh, Vassal, Gilles, Drilon, Alexander, Trent, Jonathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171956/
https://www.ncbi.nlm.nih.gov/pubmed/35672677
http://dx.doi.org/10.1186/s12885-022-09687-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171956/
https://www.ncbi.nlm.nih.gov/pubmed/35672677
http://dx.doi.org/10.1186/s12885-022-09687-x

Ejemplares similares